Drug Trial Radar · NCT04975204
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
126
Planned (sponsor's estimate)
Start
Feb 18, 2022
Primary completion
Dec 2022
Study completion Aug 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.
Conditions
- Advanced Malignant Tumor
Interventions
TQB3909 TabletsDrug
TQB3909 is an inhibitor targeting BCL-2 protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity(DLT)Time frame: up to 18 months
- Recommended Phase II Dose (RP2D)Time frame: up to 18 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.